APA (7th ed.) Citation

Pfeuffer, S., Schmidt, R., Straeten, F. A., Pul, R., Kleinschnitz, C., Wieshuber, M., . . . Meuth, S. G. (2019). Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation. Journal of neurology, 266(1), . https://doi.org/10.1007/s00415-018-9117-z

Chicago Style (17th ed.) Citation

Pfeuffer, Steffen, et al. "Efficacy and Safety of Alemtuzumab Versus Fingolimod in RRMS After Natalizumab Cessation." Journal of Neurology 266, no. 1 (2019). https://doi.org/10.1007/s00415-018-9117-z.

MLA (9th ed.) Citation

Pfeuffer, Steffen, et al. "Efficacy and Safety of Alemtuzumab Versus Fingolimod in RRMS After Natalizumab Cessation." Journal of Neurology, vol. 266, no. 1, 2019, https://doi.org/10.1007/s00415-018-9117-z.